What has changed since the last analysis (19/05/2026): the note retreated from 5,9 to 5,5. Three weeks ago, the focus was the 14% cut in the April dividend and the distance of 17% from the annual guide. Now a more delicate problem is added: the non-core position in MCEM11, which is worth almost a quarter of the fund's assets, is at the heart of an open governance crisis. The AGO ATA published today in FundosNET places the MFII11 in an isolated minority of 15,23%.
The key event: 84,77% of the MCEM11 unit holders say "no"
The ATA of the MCEM11 Ordinary General Assembly, published in 22/05/2026, records what is rarely seen in the FIIs market: the massive rejection of annual financial statements. They were. 84,77% of the contrary votes the approval of the balance sheet of 2025, against only 15,23% favourable. There was no exception from the independent auditor — the DFs were technically in order.
What weighs is what the ATA no Bring it. There is no record of a formal justification articulated by the unit base that rejected the accounts. The number, however, is eloquent for itself: when more than four out of five unit holders vote against a balance sheet without reservation, the message is of institutional mistrust, not of accounting problems. A new assembly will be convened to deliberate again.
The structural detail matters: the MFII11 holds 22,75% of the MCEM11 units. Added to the fund manager Merit and close allies, it is almost certain that the favorable block of 15,23% is composed precisely by this minority. In other words, the MFII11 voted — and lost by wide margin. The fund manager was isolated within the vehicle in which she is the largest individual unit.
MCEM11: dual risk layer over PL 22,75%
MCEM11 was no longer a comfortable position. The dividends of the fund are suspended since the delay of the City of São Paulo in the flow of payments of the housing units delivered, with resumed projected only for 2027. This means that this share of R$ 149,9 million of the MFII11 heritage is in practice generating zero current revenue.
Now comes the second layer: governance. The rejection of the DFs indicates that the MCEM11 unit base does not trust the current management or the way the numbers were presented. In subsequent meetings, it is feasible that more sensitive agendas will come — replacement of fund manager, change of regulation, partial settlement, request for special audit. Any of them can force a reassessment of the value of the units that MFII11 loads on its own VP.
This is the sensitive point for those who hold MFII11 with the "historical discount" thesis. The VP/unit of R$ 95,08 incorporates the MCEM11 units marked to a value that, in theory, should reflect the underlying patrimony. If there is impairment, more aggressive market marking or discount settlement, the VP/unit falls — and the P/VP of 0,56 starts to reflect, in fact, a VP inflated by a stressed position.
The solid core keeps delivering
Despite the noise, it is unfair to read MFII11 only by MCEM11. The core of the background remains the development of ventures in My House My Life, and this gear continues to operate well. There are 34 assets in the landbank, with VGV of R$ 1,136 billion and 14 works running. The new acquisition in Sapopemba, with 184 units and VGV of R$ 45 millions, shows that pipeline origin did not stop — on the contrary, it continues to benefit from a market with chronic housing deficit and subsidized funding.
In almost thirteen years of history, the MFII11 delivered cumulative return of +312,5% since IPO, equivalent to ICD's 160% in the period. It's not trivial. The structural thesis — social real estate development with cycles of 24 to 36 months generating recurrent capital gain — works. The current problem is that the noise of a non-core position of 22,75% is contaminating market reading over the entire asset.
The dividend in free fall
The trajectory of the DPS in 2026 tells the rest of the story. January paid R$ 1,15, February and March revolved around R$ 1,06, and April fell to R$ 0,91 — the lowest level since July 2023. Yearly, they are R$ 10,92 by unit, against a R$ 13,15. fund manager guide 17% is missing to deliver the promise.
The reason is always in this background profile: distribution depends on sales of units, and the delivery schedule in 2026 is concentrated in the second semester. But the investor who entered the consistent Yield thesis is seeing the payment drop almost 21% in four months, just when the bad news about MCEM11 arrives.
Valuation: opportunity or trap?
0,56 P/VP is the widest discount in recent MFII11 history. In theory, buying R$ 53,20 an accounting equity of R$ 95,08 per unit should be an obvious opportunity. There are two honest ways to read this number.
Optimistic reading: the market has set the worst possible scenario — dividend cutting, MCEM11 zeroed, Selic high indefinitely. In any normalization (Selic's downfall over 2027, resumption of SP City Hall payments, governance resolution in the MCEM11), the discount closes fast. CDI's historical return of 160% supports the thesis.
Careful reading: P/VP is a fraction — and the denominator (VP) can shrink. If MCEM11 suffers impairment of 30% in the units that MFII11 loads, it is R$ 45 million less in PL, or about R$ 6,60 per unit less in VP. The "real" P/VP would rise from 0,56 to 0,60. It's not catastrophic, but it's the kind of adjustment that destroys the perception of "obvious bargain."
Verdict: KEEP — Note 5,5
For whom it is: investor who already has MFII11 in portfolio with conviction about the MCMV core, 3+ years horizon and stomach for short-term volatility. The current price reflects a bad scenario, and part of this scenario can still get worse before improving — but the asset keeps delivering pipeline and has long track record.
For those who are not: investor who entered the thesis of "yield 19% sustainable" or the narrative of "P/VP cheap without risk". Both points are under attack now. Those who need monthly income predictability have less turbulent alternatives. Augmentation of position requires explicit comfort with the risk MCEM11 — it is not a pure discount trade.
How MFII11 compares to pairs
In the development segment and hybrids with income bias, the most used comparable are: TGAR11 (note 5,6) and HOSI11 (note 6,6). O TGAR11 suffers from the same typical developmental volatility, with irregular DPS and pessimistic market — but without a non-core position the size of the MCEM11 pulling reputation down. O HOSI11, in the hospital segment, it is completely different structure, with atypical rent revenue and stable governance, and precisely for this reason carries prize.
| Ticker | Segment | Note | P/VP | DY 12m | Verdict |
|---|---|---|---|---|---|
| MFII11 | MCMV Developer | 5,5 | 0,56 | 19,47% | MANTER |
| TGAR11 | Hybrid development | 5,6 | 0,82 | 14,1% | MANTER |
| HOSI11 | Hospital | 6,6 | 0,89 | 11,3% | COMPRAR |
The MFII11 offers the highest discount and the largest DY in the group, but also the highest burden of idiosyncratic uncertainty today. For the investor who wants exposure to development without noise MCEM11, TGAR11 is the cleanest alternative, even with prize. For those who prioritize income stability, the HOSI11 remains the reference of the hospital cutout.
What to monitor in the next 60 days
Three triggers define whether the note goes back up or continues to fall. First, the summoning and the result of the new AGO of the MCEM11 — if it is proposed to change fund manager or special audit, stress rises. Second, the May DPS: another sequential cut confirms deterioration; stabilization in R$ 0,90–0,95 signals that April was the floor. Third, any statement from the fund manager about marking MCEM11 units in the next monthly report — silence is tolerable, any down adjustment needs to be explained.
MFII11 didn't become a bad asset. You've become an asset with a visible problem, and the market is charging that visibility for the price. The 5,5 note reflects exactly this: it is still keeping, but the space for "everything works" has shrunk.
